Pharmaceutical industry – Page 51
-
Business
J&J buys Aragon’s prostate cancer arm
Hormone cancer specialist spins out other programmes before sale
-
BusinessTwo way traffic for Chinese drug licensing
Western companies are seeing more value in Chinese innovation
-
Business
Boehringer to close manufacturing plants and cut jobs
Two US plants and a total of 640 jobs to go by the end of next year
-
News
Chinese drug watchdog set for major reforms
Measures will speed up drug approvals and decentralise controls on generics
-
NewsIndian U-turn on diabetes drug ban
Suspension of cheap and popular medicine reversed but will now come with new safety warnings
-
Business
Antiviral patents released by Roche
Firm will supply cheap drugs and allow generics in developing countries
-
NewsExecution drug cannot be imported into US
Court rules that the Food and Drug Administration acted unlawfully allowing sodium thiopental into the country
-
Business
India revokes more pharma patents
Original molecule patent stands, but a new salt form is ‘not innovative’
-
BusinessPfizer reshuffle hints at future split decision
Could pharma giant’s ‘value’ and ‘innovative’ segments get broken apart?
-
Business
Perrigo bags Elan and its bargain Irish tax rates
$8.6bn deal ends Elan’s takeover battle with Royalty Pharma
-
Business
Thousands face job cuts after Valeant's Bausch buyout
Valeant plans to shed 10-15% of its workforce to save $800 million
-
BusinessChina corruption investigation broadens
GSK scandal is the trigger to clean up Chinese drug market
-
BusinessLilly freezes pay as patent cliff looms
Drugmaker targets $400 million savings as two key patents near expiry
-
Business
GSK under investigation over corruption in China
Police claim executives engaged in bribery and tax-related crimes
-
Business
Evotec moves business back to UK
Pharma company closes operations in India, citing distance from customers
-
Business
Biosimilar drugs step up complexity
First generic monoclonal antibodies recommended for approval in Europe
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Aspen in $1 billion deal with Merck & Co
South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires